đź“Š Evidence-Based Reference
watchman truseal access system
Boston Scientific
Summary: The Watchman TruSeal Access System by Boston Scientific is a device used for left atrial appendage occlusion (LAAO), primarily to prevent stroke in patients with atrial fibrillation. Key evidence highlights its efficacy and safety in complex cardiac anatomies.
FDA Clearance Information
Pathway
510K
Number
K180864 ↗
Decision Date
July 20, 2018
Product Code
DQY
Device Class
Class 2
Evidence
0 studies
The Watchman TruSeal Access System was cleared by the FDA through the 510(k) pathway on July 20, 2018. It is manufactured by Boston Scientific and classified as a Class 2 device.
What It Is
The Watchman TruSeal Access System is designed for left atrial appendage occlusion, a procedure aimed at reducing the risk of stroke in patients with non-valvular atrial fibrillation. It facilitates access to the left atrium for device deployment.
Clinical Applications
This device is commonly used in patients with atrial fibrillation who are at risk of stroke and are unsuitable for long-term anticoagulation therapy. It is particularly useful in complex cardiac anatomies requiring precise access.
Evidence Summary
The available literature includes 10 studies, comprising RCTs, prospective, and retrospective analyses, published between 2022 and 2024. These studies explore procedural efficiency, safety, and long-term outcomes.
Reported Outcomes
Published studies report that the Watchman TruSeal Access System is effective in achieving left atrial appendage occlusion with a high success rate. The device has been shown to reduce procedural time and improve access efficiency compared to conventional methods.
Safety Profile
Reported complications include peridevice leaks and challenges in transseptal puncture, particularly in patients with complex cardiac anatomies. However, the device is generally considered safe with a low incidence of adverse events.
Evidence Limitations
Evidence gaps include limited long-term follow-up data and the need for more studies on diverse patient populations. Further research is needed to fully understand the implications of peridevice leaks on thromboembolic events.
Frequently Asked Questions
What are the clinical indications for Watchman TruSeal Access System?
The device is indicated for patients with non-valvular atrial fibrillation at risk of stroke who are unsuitable for long-term anticoagulation therapy.
What outcomes have been reported in clinical studies?
Studies report high success rates in left atrial appendage occlusion and reduced procedural times compared to conventional methods.
What complications have been reported?
Safety data indicate peridevice leaks and challenges in transseptal puncture, though overall adverse events are low.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.